DSPE-PEG2000-DBCO
Based on 1 publication(s) in Google Scholar
DSPE-PEG2000-DBCO is a phospholipid PEG polymer that combines a hydrophobic phospholipid (DSPE), a hydrophilic polyethylene glycol spacer with a molecular weight of 1000 Da, and a reactive click chemistry terminal group (DBCO). DSPE-PEG2000-DBCO migrates to lymph nodes via the endogenous albumin transport system, implants bioorthogonal DBCO docking sites, and enables the enrichment of azide-functionalized vesicles in lymph nodes mediated by click chemistry. DSPE-PEG2000-DBCO can be used in studies related to atherosclerosis.
For research use only. We do not sell to patients.
- Purity : 99.90%
- Formula: (C2H4O)nC43H86NO9P
- Molecular Weight:2000 (Average)
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DSPE-PEG2000-DBCO
More
Biological Activity
Description
In Vitro
DSPE-PEG2000-DBCO can be designed as the first dose (pretargeting anchor) of the two-component sonodynamic vaccine SenoVac: it efficiently migrates into lymph nodes via hitchhiking on endogenous albumin, pre-installs bioorthogonal DBCO docking sites in lymph nodes, and specifically and durably locks the azide-modified SCAV in lymph nodes through copper-free click chemistry when the second dose arrives[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
DSPE-PEG2000-DBCO (s.c.; single dose) achieves effective and sustained lymph node labeling, with fluorescence peaking at 24 hours and remaining detectable for up to 120 hours[1].
DSPE-PEG2000-DBCO (s.c.; administered prior to each vaccination dose) as part of the SenoVac platform reduces plaque senescent cell burden and attenuates atherosclerosis progression in high-fat diet-fed ApoE-/- mice[1].
DSPE-PEG2000-DBCO (s.c.; administered prior to N3-SCAVᴴᴿ) as part of the SenoVac platform reduces senescent cell burden across multiple organs in p16-tdTomato reporter mice, with efficacy enhanced by ultrasound stimulation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6-8-week-old)[1]
-
Dosage:60 nmol
-
Administration:s.c.; single dose
-
Result:Exhibited approximately threefold higher lymph node fluorescence than DSPE-PEG-pretreated controls.
Showed strong fluorescence localized predominantly in draining lymph nodes, with moderate liver uptake and minimal signal in heart, spleen, lung, and kidney.
Chemical Information
-
Appearance Solid
-
Molecular Weight 2000 (Average)
-
Formula (C2H4O)nC43H86NO9P
-
Color White to light yellow
-
SMILES
CCCCCCCCCCCCCCCCCC(OC[C@](OC(CCCCCCCCCCCCCCCCC)=O)([H])COP(O)(OCCNC(OCCNC(CCCCC(N1C(C=CC=C2)=C2C#CC(C=CC=C3)=C3C1)=O)=O)=O)=O)=O.[n]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy. [Abstract]2026 May 20:e75770. PMID: 42159453
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DSPE-PEG2000-DBCO Related Classifications
HY-W440835 Related Classifications
Powered by Bioz